July has been a big month for Novotech in South Korea. The Australian-based CRO that operates in 13 countries made two announcements aimed at furthering its presence in one of the hottest CRO markets in the Asia-Pacific region. On July 19 Novotech announced that they launched a new site management organization (SMO) in South Korea. And on July 26 the company announced that it signed a Memorandum of Understanding (MOU) with South Korea’s SCI-Consortium (SCIC) of Clinical Trial Centers and its representative hospital, Severance Hospital, Yonsei University Health System.

Other relevant content